RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Chongqing Lummy Pharmaceutical Co Stock

Chongqing Lummy Pharmaceutical Co Stocks 2024

Chongqing Lummy Pharmaceutical Co Stocks

1.06 B

Ticker

300006.SZ

ISIN

CNE100000H10

In 2024, Chongqing Lummy Pharmaceutical Co had 1.06 B outstanding stocks, a 0% change from the 1.06 B stocks in the previous year.

The Chongqing Lummy Pharmaceutical Co Stocks history

YEARNUMBER OF STOCKS (undefined CNY)
20231.06
20221.06
20211
20200.81
20190.81
20180.81
20170.81
20160.81
20150.81
20140.73
20130.68
20120.66
20110.66
20100.66
20090.53
20080.49
20070.31
20060.18

Chongqing Lummy Pharmaceutical Co shares outstanding

The number of shares was Chongqing Lummy Pharmaceutical Co in 2023 — This indicates how many shares 1.056 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Chongqing Lummy Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chongqing Lummy Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chongqing Lummy Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chongqing Lummy Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chongqing Lummy Pharmaceutical Co Aktienanalyse

What does Chongqing Lummy Pharmaceutical Co do?

Chongqing Lummy Pharmaceutical Co Ltd is a leading company in the pharmaceutical products sector. The company was founded in 2001 and is headquartered in Chongqing, China. Its business model focuses on the manufacturing and distribution of pharmaceutical products and medications, including those for the treatment of severe and chronic diseases. Since its establishment, the company has undergone significant development. Through the establishment of research and development departments, the company has been able to develop and manufacture innovative products. This has enabled the company to establish itself as an important player in the market. Chongqing Lummy Pharmaceutical's main products include medications for the treatment of diabetes, cancer, cardiovascular diseases, and mental disorders. The divisions of Chongqing Lummy Pharmaceutical cover various areas of pharmaceutical manufacturing, including the production of tablets, capsules, injection fluids, and ointments. There is also a department specializing in the production of raw materials and active ingredients. This allows Chongqing Lummy Pharmaceutical to control its own value chain and ensure the quality of its products. The company's most well-known products include the insulin injection fluids "Liupanshui," which have been very successful in the Chinese market. The medications "Qiliqiang" and "Jiaonang" for the treatment of breast cancer and the severe acute respiratory syndrome SARS-CoV-2 have also been very successful. The company also has a strong presence in other Asian countries, such as India and Vietnam. Chongqing Lummy Pharmaceutical focuses on quality and innovation. The company holds several certifications and has established a quality assurance system to ensure that all products meet the highest standards. Additionally, the company invests heavily in research and development to bring innovative products to the market. Chongqing Lummy Pharmaceutical also participates in research projects with other companies and institutions to promote collaboration in the pharmaceutical industry. In recent years, the company has achieved strong growth. It has a wide portfolio of products and a strong presence in Asia. In the future, the company plans to further expand its market position and broaden its product range. Chongqing Lummy Pharmaceutical has good chances of establishing itself as a major player in the global market for pharmaceutical products. Chongqing Lummy Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Chongqing Lummy Pharmaceutical Co's Shares Outstanding

Chongqing Lummy Pharmaceutical Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Chongqing Lummy Pharmaceutical Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Chongqing Lummy Pharmaceutical Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Chongqing Lummy Pharmaceutical Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Chongqing Lummy Pharmaceutical Co stock

How many stocks are there of Chongqing Lummy Pharmaceutical Co?

The current number of stocks of Chongqing Lummy Pharmaceutical Co is 1.06 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Chongqing Lummy Pharmaceutical Co are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Chongqing Lummy Pharmaceutical Co evolved in recent years?

The number of shares of Chongqing Lummy Pharmaceutical Co has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Chongqing Lummy Pharmaceutical Co as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Chongqing Lummy Pharmaceutical Co?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Chongqing Lummy Pharmaceutical Co pay?

Over the past 12 months, Chongqing Lummy Pharmaceutical Co paid a dividend of 0.05 CNY . This corresponds to a dividend yield of about 1.03 %. For the coming 12 months, Chongqing Lummy Pharmaceutical Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Chongqing Lummy Pharmaceutical Co?

The current dividend yield of Chongqing Lummy Pharmaceutical Co is 1.03 %.

When does Chongqing Lummy Pharmaceutical Co pay dividends?

Chongqing Lummy Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of August, September, August, August.

How secure is the dividend of Chongqing Lummy Pharmaceutical Co?

Chongqing Lummy Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Chongqing Lummy Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chongqing Lummy Pharmaceutical Co located?

Chongqing Lummy Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chongqing Lummy Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chongqing Lummy Pharmaceutical Co from 7/3/2020 amounting to 0.05 CNY, you needed to have the stock in your portfolio before the ex-date on 7/3/2020.

When did Chongqing Lummy Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 7/3/2020.

What was the dividend of Chongqing Lummy Pharmaceutical Co in the year 2023?

In the year 2023, Chongqing Lummy Pharmaceutical Co distributed 0 CNY as dividends.

In which currency does Chongqing Lummy Pharmaceutical Co pay out the dividend?

The dividends of Chongqing Lummy Pharmaceutical Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Chongqing Lummy Pharmaceutical Co

Our stock analysis for Chongqing Lummy Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chongqing Lummy Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.